# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:MDWD) with a Buy and maintains $28 price...
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.44) b...
MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced th...
Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and ...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:MDWD) with a Buy and maintains $28 price...
- SEC Filing
Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announ...